Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28055393 | 0.98 | NPC1 (0.33) | NPC1KDM1AALDH1A1LMNACYP1A2 | |
| SCHEMBL31364603 | 0.83 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31364605 | 0.83 | ALDH1A1 (0.31) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL11289554 | 0.79 | — | — | |
| SCHEMBL3379483 | 0.79 | — | — | |
| SCHEMBL1373825 | 0.79 | — | — | |
| SCHEMBL7333427 | 0.79 | CA12 (0.37) | ALDH1A1LMNA | |
| Histamine SCHEMBL32672530 | 0.78 | — | — | |
| SCHEMBL17654953 | 0.78 | EPHX2 (0.33) | ALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL1423332 | 0.78 | HRH3 (0.44) | ALDH1A1LMNAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557989-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130213822-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8293904-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8288544-B2 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-1646637-B1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-15 | — | — | EP | disclosed |
| EP-2465862-A1 | Mononuclear osmium complexes for use in biosensors | Roche Diagniostics GmbH (DE) | 2012-06-20 | — | — | EP | disclosed |
| US-20120125788-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2012-05-24 | — | — | US | disclosed |
| US-20070054317-A1 | Electrochemical affinity biosensor system and methods | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2007-03-08 | — | — | US | disclosed |
| EP-1646637-A2 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | Roche Diagnostics GmbH (DE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005026178-A2 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | ROCHE DIAGNOSTICS GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054317-A1 | Electrochemical affinity biosensor system and methods | SIGLEC7, FCGR3B, FCER2 | NPC1 3465/4885KDM1A 4683/4885ALDH1A1 1343/4885 |
| US-20130213822-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | SIGLEC7, FCGR3B, FCER2 | NPC1 3465/4885KDM1A 4683/4885ALDH1A1 1343/4885 |
| US-20120125788-A1 | ELECTROCHEMICAL AFFINITY BIOSENSOR SYSTEM AND METHODS | SIGLEC7, FCGR3B, FCER2 | NPC1 3465/4885KDM1A 4683/4885ALDH1A1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.